March 26th 2025
Delandistrogene moxeparvovec, a gene therapy approved for the treatment of Duchenne muscular dystrophy (DMD), was found tolerable and showed signs of efficacy in a real-world cohort.
February 27th 2025
Data on Delandistrogene Moxeparvovec Can Inform Future Gene Therapies
Despite Risk, Patients With SCD Hopeful About Gene Therapies